Neurocrine Biosciences (NBIX) Competitors $156.70 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$158.00 +1.30 (+0.83%) As of 05/22/2026 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBIX vs. ALNY, BIIB, UTHR, INCY, and EXELShould you buy Neurocrine Biosciences stock or one of its competitors? MarketBeat compares Neurocrine Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. NBIX vs. ALNYNBIX vs. BIIBNBIX vs. UTHRNBIX vs. INCYNBIX vs. EXELHow does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?Neurocrine Biosciences (NASDAQ:NBIX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Do insiders and institutionals believe in NBIX or ALNY? 92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, NBIX or ALNY? Neurocrine Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Is NBIX or ALNY more profitable? Neurocrine Biosciences has a net margin of 21.55% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Neurocrine Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences21.55% 19.79% 13.82% Alnylam Pharmaceuticals 11.72%85.76%10.32% Do analysts prefer NBIX or ALNY? Neurocrine Biosciences presently has a consensus price target of $185.90, indicating a potential upside of 18.64%. Alnylam Pharmaceuticals has a consensus price target of $463.13, indicating a potential upside of 55.70%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Neurocrine Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83Alnylam Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 2.85 Does the media prefer NBIX or ALNY? In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for Alnylam Pharmaceuticals and 20 mentions for Neurocrine Biosciences. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat Neurocrine Biosciences' score of 0.51 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 17 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, NBIX or ALNY? Neurocrine Biosciences has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.86B5.51$478.60M$6.4924.14Alnylam Pharmaceuticals$3.71B10.69$313.75M$3.6681.27 SummaryAlnylam Pharmaceuticals beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks.How does Neurocrine Biosciences compare to Biogen?Neurocrine Biosciences (NASDAQ:NBIX) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment. Do analysts recommend NBIX or BIIB? Neurocrine Biosciences currently has a consensus target price of $185.90, indicating a potential upside of 18.64%. Biogen has a consensus target price of $215.62, indicating a potential upside of 11.28%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83Biogen 1 Sell rating(s) 13 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.52 Does the media refer more to NBIX or BIIB? In the previous week, Biogen had 1 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 21 mentions for Biogen and 20 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.51 beat Biogen's score of 0.31 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 7 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Is NBIX or BIIB more profitable? Neurocrine Biosciences has a net margin of 21.55% compared to Biogen's net margin of 13.81%. Neurocrine Biosciences' return on equity of 19.79% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences21.55% 19.79% 13.82% Biogen 13.81%12.83%8.01% Do insiders and institutionals believe in NBIX or BIIB? 92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger earnings and valuation, NBIX or BIIB? Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.86B5.51$478.60M$6.4924.14Biogen$9.89B2.89$1.29B$9.3220.79 Which has more risk & volatility, NBIX or BIIB? Neurocrine Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Biogen has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. SummaryNeurocrine Biosciences beats Biogen on 12 of the 16 factors compared between the two stocks.How does Neurocrine Biosciences compare to United Therapeutics?Neurocrine Biosciences (NASDAQ:NBIX) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends. Does the media favor NBIX or UTHR? In the previous week, United Therapeutics had 3 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 23 mentions for United Therapeutics and 20 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.51 beat United Therapeutics' score of 0.37 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 11 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend NBIX or UTHR? Neurocrine Biosciences currently has a consensus price target of $185.90, indicating a potential upside of 18.64%. United Therapeutics has a consensus price target of $619.42, indicating a potential upside of 8.97%. Given Neurocrine Biosciences' higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83United Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85 Which has higher valuation & earnings, NBIX or UTHR? United Therapeutics has higher revenue and earnings than Neurocrine Biosciences. United Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.86B5.51$478.60M$6.4924.14United Therapeutics$3.18B7.58$1.33B$27.0920.98 Do insiders & institutionals believe in NBIX or UTHR? 92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is NBIX or UTHR more profitable? United Therapeutics has a net margin of 40.62% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat United Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences21.55% 19.79% 13.82% United Therapeutics 40.62%19.24%17.25% Which has more volatility and risk, NBIX or UTHR? Neurocrine Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. SummaryUnited Therapeutics beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks.How does Neurocrine Biosciences compare to Incyte?Neurocrine Biosciences (NASDAQ:NBIX) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations. Do analysts rate NBIX or INCY? Neurocrine Biosciences presently has a consensus price target of $185.90, indicating a potential upside of 18.64%. Incyte has a consensus price target of $104.00, indicating a potential upside of 7.04%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83Incyte 1 Sell rating(s) 11 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.41 Is NBIX or INCY more profitable? Incyte has a net margin of 26.71% compared to Neurocrine Biosciences' net margin of 21.55%. Incyte's return on equity of 26.66% beat Neurocrine Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences21.55% 19.79% 13.82% Incyte 26.71%26.66%19.77% Which has preferable earnings and valuation, NBIX or INCY? Incyte has higher revenue and earnings than Neurocrine Biosciences. Incyte is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.86B5.51$478.60M$6.4924.14Incyte$5.14B3.78$1.29B$7.0813.72 Which has more risk and volatility, NBIX or INCY? Neurocrine Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Do insiders and institutionals believe in NBIX or INCY? 92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor NBIX or INCY? In the previous week, Neurocrine Biosciences had 5 more articles in the media than Incyte. MarketBeat recorded 20 mentions for Neurocrine Biosciences and 15 mentions for Incyte. Incyte's average media sentiment score of 0.90 beat Neurocrine Biosciences' score of 0.51 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 5 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryIncyte beats Neurocrine Biosciences on 10 of the 17 factors compared between the two stocks.How does Neurocrine Biosciences compare to Exelixis?Neurocrine Biosciences (NASDAQ:NBIX) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations. Do institutionals & insiders have more ownership in NBIX or EXEL? 92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 2.6% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend NBIX or EXEL? Neurocrine Biosciences presently has a consensus price target of $185.90, suggesting a potential upside of 18.64%. Exelixis has a consensus price target of $47.35, suggesting a potential downside of 5.58%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Neurocrine Biosciences is more favorable than Exelixis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83Exelixis 2 Sell rating(s) 11 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.39 Is NBIX or EXEL more profitable? Exelixis has a net margin of 35.08% compared to Neurocrine Biosciences' net margin of 21.55%. Exelixis' return on equity of 39.89% beat Neurocrine Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences21.55% 19.79% 13.82% Exelixis 35.08%39.89%30.23% Which has more risk and volatility, NBIX or EXEL? Neurocrine Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Does the media refer more to NBIX or EXEL? In the previous week, Exelixis had 7 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 27 mentions for Exelixis and 20 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.51 beat Exelixis' score of 0.32 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 9 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Which has higher earnings and valuation, NBIX or EXEL? Exelixis has lower revenue, but higher earnings than Neurocrine Biosciences. Exelixis is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.86B5.51$478.60M$6.4924.14Exelixis$2.32B5.43$782.57M$3.0116.66 SummaryNeurocrine Biosciences beats Exelixis on 10 of the 16 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition ExportMetricNeurocrine BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.76B$3.04B$6.45B$12.34BDividend YieldN/A1.97%2.76%5.28%P/E Ratio24.1417.7921.2225.65Price / Sales5.51336.21553.9286.28Price / Cash31.2657.7443.4956.67Price / Book4.625.8610.377.14Net Income$478.60M$74.99M$3.57B$335.98M7 Day Performance-0.32%2.55%6.01%3.56%1 Month Performance22.75%-3.05%3.52%2.54%1 Year Performance30.39%34.38%34.13%35.05% Neurocrine Biosciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences3.8269 of 5 stars$156.70flat$185.90+18.6%+30.4%$15.76B$2.86B24.142,000Analyst ForecastALNYAlnylam Pharmaceuticals4.7134 of 5 stars$286.27-0.2%$471.96+64.9%+2.6%$38.32B$3.71B78.222,770Positive NewsBIIBBiogen3.8302 of 5 stars$191.91-0.5%$215.62+12.4%+54.0%$28.49B$9.89B20.597,500UTHRUnited Therapeutics3.9285 of 5 stars$566.99-0.3%$619.42+9.2%+84.8%$24.13B$3.18B20.931,400Insider TradeINCYIncyte4.6313 of 5 stars$95.19-0.1%$104.26+9.5%+51.2%$19.04B$5.14B13.442,844Positive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Incyte Competitors Exelixis Competitors Ionis Pharmaceuticals Competitors Madrigal Pharmaceuticals Competitors BioMarin Pharmaceutical Competitors Halozyme Therapeutics Competitors Alkermes Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
